Thus, patients with secondary ITP have an underlying autoimmune disease, and the polymorphisms found in the CTLA4 promoter could be related to the underlying autoimmune disease, and not necessarily to the development of ITP. Here, CTLA4 is linked to autoimmune thrombocytopenic purpura.